E. Pazos; M. García-Algar; C. Penas; M. Nazarenus; A.Torruella; N. Pazos- Perez; L. Guerrini; M.E. Vázquez; E. García-Rico; J.L. Mascareñas; R.A. Alvarez-Puebla ;
Journal of the American Chemical Society, (2016) (DOI:10.1021/jacs.6b08957)
Blood-based biomarkers (liquid biopsy) offer extremely valua-ble tools for the non-invasive diagnosis and monitoring of tumors. The protein c-MYC, a transcription factor that has been shown to be deregulated in up to 70% of human cancers, can be used as a robust proteomic signature for cancer. Herein, we developed a rapid, highly specific and sensitive SERS assay for the quantification of c-MYC in real blood samples. The sensing scheme relies on the use of specifically designed hybrid plasmonic materials and their bioderivatization with a selective peptidic receptor modified with a SERS transducer. Peptide/c-MYC recognition events translate into measurable alterations of the SERS spectra associated with a molecular re-orientation of the transducer, in agreement with the surface selection rules. The efficiency of the sensor is demonstrated in cellular lines, healthy donors and a cancer patient.
Anna Cuadras & Enric Rovira & Rosa Maria Marcé & Francesc Borrull
Environ Sci Pollut Res- DOI: 10.1007/s11356-016-7566-4
Abstract: DThis study focuses on characterizing the chronic risk assessment from inhalation of polycyclic aromatic hydrocarbons (PAHs) for people living near the largest chemical complex in the Mediterranean area. Eighteen PAHs were determined in the atmospheric gas and particle phases, counting PM10 and total suspended particles. The lifetime lung cancer risk from PAH exposure was estimated, and the contribution was assessed by phases. The results obtained with the continuous lifetime scenario were compared with those obtained with different chronic scenarios. The estimated chronic risk was also compared with those reported in previous studies.
PAHs were present at higher concentration in the gas phase (>84 %) with a major contribution of the most volatile PAHs, and an equitable distribution of heavy PAHs between gas and particle phases was observed. Petroleum combustion and traffic emissions were suggested as the main sources, but the influence of petrogenic sources cannot be ruled out. The estimated average lifetime lung cancer risk in this study ranged
Carme Catala, Bernat Mir-Simon, Xiaotong Feng, Celia Cardozo, Nicolas Pazos-Perez, Elena Pazos, Sara Gómez-de Pedro, Luca Guerrini, Alex Soriano, Jordi Vila, Francec Marco, Eduardo Garcia-Rico and Ramon A. Alvarez-Puebla
Advanced Materials Technologies - DOI: 10.1002/admt.201600163
Abstract: Efficient treatments in bacterial infections require the fast and accurate recognition of pathogens, with concentrations as low as one per milliliter in the case of septicemia. Detecting and quantifying bacteria in such low concentrations is challenging and typically demands cultures of large samples of blood (~1 milliliter) extending over 24–72 hours. This delay seriously compromises the health of patients. Here we demonstrate a fast microorganism optical detection system for the exhaustive identification and quantification of pathogens in volumes of biofluids with clinical relevance (~1 milliliter) in minutes. We drive each type of bacteria to accumulate antibody functionalized SERS-labelled silver nanoparticles. Particle aggregation on the bacteria membranes renders dense arrays of inter-particle gaps in which the Raman signal is exponentially amplified by several orders of magnitude relative to the dispersed particles. This enables a multiplex identification of the microorganisms through the molecule-specific spectral fingerprints.
|TECNIOspring PLUS is ACCIÓ's fellowship programme. It provides financial support to individual mobility proposals presented by experienced researchers in liaison with a host organisation. Fellows are offered 2-year employment contracts in order to develop applied research projects.|
|ACCIÓ posa en marxa noves convocatòries d'ajuts per impulsar la innovació i la incorporació de tecnologia a les empreses catalanes. La nova política d'innovació de la Generalitat de Catalunya destinarà més de 103 milions d'euros a projectes d'innovació d'empreses catalanes en el període 2015-2020.|